Grants first, 'obliterating' VC second the best early funding route for 'under-loved' stem cell therapies?
This article was originally published in Scrip
Executive Summary
Investors insist that they want to put money into regenerative medicine companies, but government grants and other non-dilutive financing may be more likely sources of early-stage capital for stem cell therapy developers.